News | April 10, 2026
Lupin Foundation expands NCD care access in Rajasthan with new diagnostic corners
The initiative is aimed at strengthening the district-level screening and chronic disease management infrastructure
The initiative is aimed at strengthening the district-level screening and chronic disease management infrastructure
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Recognition across subsidiaries and geographies highlights pharma major’s focus on inclusive culture, employee experience, and global workforce development
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery
These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The EIR was issued following an inspection of the facility from November 10 to November 21, 2025
Vinita has made expansion in the U.S. a core pillar of Lupin’s worldwide growth strategy
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
Subscribe To Our Newsletter & Stay Updated
